Biotech & Pharma.T.A, Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A,

BIB 88.17

+3.2%

Jan 22 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (3102)	12/3/2010 11:49:37 AM
From: Jibacoa	Read Replies (1) of 3722

CYTX is also among the few Biotechs staying on the green today.<g> The stock was up 6.75% and is still up 5.45% with volume about 3/4 its ADV bigcharts.marketwatch.com Last month CYTX reported that adipose tissue-derived regenerative cells obtained using its Celution System demonstrated a statistically significant improvement in cardiac functional capacity at 18 months in the PRECISE trial for chronic myocardial ischemia. <g> The data from that trial were presented at the American Heart Association Scientific Sessions in Chicago. Among other things, the trial demonstrated the following outcomes in no-option chronic ischemic heart disease patients: Statistically significant improvement in maximum oxygen consumption in the cell treated group compared to the control group, which was sustained at 18 months. Statistically significant improvement in patients' ability to perform physical activity,also sustained at 18 months. The procedure, which includes withdrawing fat tissue, separating out the regenerative cells using CYTX's Celution System, and re-injecting the cells into the patient's heart, has previously been found to be safe and feasible, with no safety concerns emerging during the 18-month observation period. The treated patients had a lower cardiac mortality rate compared to the control. Based on this information, CYTX plans to seek EU regulatory approval of this treatment for patients with no-option chronic ischemia in early 2011.<g> The ACTAY is $9.50 I would keep a TT at the $6 level pending further developments.<g> bigcharts.marketwatch.com Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next